PDF(Pubmed)
Abstract：
UNASSIGNED: Gait issues, including reduced speed, stride length and freezing of gait (FoG), are disabling in advanced phases of Parkinson\'s disease (PD), and their treatment is challenging. Levodopa/carbidopa intestinal gel (LCIG) can improve these symptoms in PD patients with suboptimal control of motor fluctuations, but it is unclear if continuous dopaminergic stimulation can further improve gait issues, independently from reducing Off-time.
UNASSIGNED: To analyze before (T0) and after 3 (T1) and 6 (T2) months of LCIG initiation: a) the objective improvement of gait and balance; b) the improvement of FoG severity; c) the improvement of motor complications and their correlation with changes in gait parameters and FoG severity.
UNASSIGNED: This prospective, longitudinal 6-months study analyzed quantitative gait parameters using wearable inertial sensors, FoG with the New Freezing of Gait Questionnaire (NFoG-Q), and motor complications, as per the MDS-UPDRS part IV scores.
UNASSIGNED: Gait speed and stride length increased and duration of Timed up and Go and of sit-to-stand transition was significantly reduced comparing T0 with T2, but not between T0-T1. NFoG-Q score decreased significantly from 19.3±4.6 (T0) to 11.8±7.9 (T1) and 8.4±7.6 (T2) (T1-T0 p = 0.018; T2-T0 p < 0.001). Improvement of MDS-UPDRS-IV (T0-T2, p = 0.002, T0-T1 p = 0.024) was not correlated with improvement of gait parameters and NFoG-Q from T0 to T2. LEDD did not change significantly after LCIG initiation.
UNASSIGNED: Continuous dopaminergic stimulation provided by LCIG infusion progressively ameliorates gait and alleviates FoG in PD patients over time, independently from improvement of motor fluctuations and without increase of daily dosage of dopaminergic therapy.
UNASSIGNED: To analyze before (T0) and after 3 (T1) and 6 (T2) months of LCIG initiation: a) the objective improvement of gait and balance; b) the improvement of FoG severity; c) the improvement of motor complications and their correlation with changes in gait parameters and FoG severity.
UNASSIGNED: This prospective, longitudinal 6-months study analyzed quantitative gait parameters using wearable inertial sensors, FoG with the New Freezing of Gait Questionnaire (NFoG-Q), and motor complications, as per the MDS-UPDRS part IV scores.
UNASSIGNED: Gait speed and stride length increased and duration of Timed up and Go and of sit-to-stand transition was significantly reduced comparing T0 with T2, but not between T0-T1. NFoG-Q score decreased significantly from 19.3±4.6 (T0) to 11.8±7.9 (T1) and 8.4±7.6 (T2) (T1-T0 p = 0.018; T2-T0 p < 0.001). Improvement of MDS-UPDRS-IV (T0-T2, p = 0.002, T0-T1 p = 0.024) was not correlated with improvement of gait parameters and NFoG-Q from T0 to T2. LEDD did not change significantly after LCIG initiation.
UNASSIGNED: Continuous dopaminergic stimulation provided by LCIG infusion progressively ameliorates gait and alleviates FoG in PD patients over time, independently from improvement of motor fluctuations and without increase of daily dosage of dopaminergic therapy.
摘要：
■步态问题，包括降低速度，步幅和步态冻结（FoG），在帕金森病（PD）的晚期致残，他们的治疗具有挑战性。左旋多巴/卡比多巴肠道凝胶（LCIG）可以改善PD患者的这些症状，对运动波动控制不佳，但尚不清楚连续多巴胺能刺激是否能进一步改善步态问题，独立减少休息时间。
■分析LCIG开始前（T0）和后3（T1）和6（T2）个月：a）步态和平衡的客观改善；b）FoG严重程度的改善；c）运动并发症的改善及其与步态参数和FoG严重程度变化的相关性。
■这个前景，纵向6个月研究使用可穿戴惯性传感器分析定量步态参数，FoG与新的步态冻结问卷（NFoG-Q），和运动并发症，根据MDS-UPDRS第四部分的分数。
■与T0和T2相比，步态速度和步幅增加，Timedup和Go以及从坐到站过渡的持续时间显着减少，但在T0-T1之间没有。NFoG-Q评分从19.3±4.6（T0）降至11.8±7.9（T1）和8.4±7.6（T2）（T1-T0p=0.018；T2-T0p<0.001）。MDS-UPDRS-IV（T0-T2，p=0.002，T0-T1p=0.024）的改善与步态参数和NFoG-Q从T0到T2的改善无关。LCIG启动后，LEDD没有明显变化。
■LCIG输注提供的持续多巴胺能刺激随着时间的推移逐渐改善PD患者的步态并减轻FoG，独立于运动波动的改善，并且不增加多巴胺能治疗的每日剂量。
■分析LCIG开始前（T0）和后3（T1）和6（T2）个月：a）步态和平衡的客观改善；b）FoG严重程度的改善；c）运动并发症的改善及其与步态参数和FoG严重程度变化的相关性。
■这个前景，纵向6个月研究使用可穿戴惯性传感器分析定量步态参数，FoG与新的步态冻结问卷（NFoG-Q），和运动并发症，根据MDS-UPDRS第四部分的分数。
■与T0和T2相比，步态速度和步幅增加，Timedup和Go以及从坐到站过渡的持续时间显着减少，但在T0-T1之间没有。NFoG-Q评分从19.3±4.6（T0）降至11.8±7.9（T1）和8.4±7.6（T2）（T1-T0p=0.018；T2-T0p<0.001）。MDS-UPDRS-IV（T0-T2，p=0.002，T0-T1p=0.024）的改善与步态参数和NFoG-Q从T0到T2的改善无关。LCIG启动后，LEDD没有明显变化。
■LCIG输注提供的持续多巴胺能刺激随着时间的推移逐渐改善PD患者的步态并减轻FoG，独立于运动波动的改善，并且不增加多巴胺能治疗的每日剂量。
